Quantity of eligible patients: CDEC discussed the uncertainty in the number of people with reasonably serious to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as possessing mild or reasonable disorder could have a extreme bleeding https://hemgenix50482.blogvivi.com/36472600/the-definitive-guide-to-hemgenix